Change in peripheral blood leukocyte telomere length and mortality in breast cancer survivors

Journal of the National Cancer Institute

Volumn 106, Issue 4, 2014, Pages

  Duggan, Catherine ^a   Risques, Rosana ^b,c   Alfano, Catherine ^d   Prunkard, Donna ^b,c   Imayama, Ikuyo ^a   Holte, Sarah ^a   Baumgartner, Kathy ^e   Baumgartner, Rick ^e   Bernstein, Leslie ^f   Ballard Barbash, Rachel ^d   Rabinovitch, Peter ^b,c   McTiernan, Anne ^a,b,c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; ALL CAUSE MORTALITY; ARTICLE; BREAST CANCER; BREAST CANCER SPECIFIC MORTALITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TELOMERE; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; AGED; BLOOD; BREAST TUMOR; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; STATISTICS; SURVIVOR;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTES; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TELOMERE; TELOMERE SHORTENING;

EID: 84898862319     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju035     Document Type: Article

References (47)

1. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008;8(6):450-458.
2. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008;42:301-334.
3. Stewart SA, Weinberg RA. Telomeres: cancer to human aging. Annu Rev Cell Dev Biol. 2006;22:531-557.
4. Aviv A, Hunt SC, Lin J, et al. Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR. Nucleic Acids Res. 2011;39(20):e134.
5. Cawthon RM, Smith KR, O'Brien E, et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361(9355):393-395.
6. Cui Y, Cai Q, Qu S, et al. Association of leukocyte telomere length with colorectal cancer risk: nested case-control findings from the Shanghai Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1807-1813.
7. McGrath M, Wong JY, Michaud D, et al. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 2007;16(4):815-819.
8. Qu S, Wen W, Shu XO, et al. Association of leukocyte telomere length with breast cancer risk: nested case-control findings from the Shanghai Women's Health Study. Am J Epidemiol. 2013;177(7):617-624.
9. Shen J, Gammon MD, Terry MB, et al. Telomere length, oxidative damage, antioxidants and breast cancer risk. Int J Cancer. 2009;124(7):1637-1643.
10. Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst. 2003;95(16):1211-1218.
11. De Vivo I, Prescott J, Wong JY, et al. A prospective study of relative tel-omere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1152-1156.
12. Kim S, Sandler D P, Carswell G, et al. Telomere length in peripheral blood and breast cancer risk in a prospective case-cohort analysis: results from the Sister Study. Cancer Causes Control. 2011;22(7):1061v1066.
13. Zheng YL, Ambrosone C, Byrne C, et al. Telomere length in blood cells and breast cancer risk: investigations in two case-control studies. Breast Cancer Res Treat. 2010;120(3):769-775.
14. Ma H, Zhou Z, Wei S, et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS One. 2011;6(6):e20466.
15. Wentzensen IM, Mirabello L, Pfeiffer RM, et al. The association of tel-omere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1238-1250.
16. Pooley KA, Sandhu MS, Tyrer J, et al. Telomere length in prospective and retrospective cancer case-control studies. Cancer Res. 2010;70(8):3170-3176.
17. Svenson U, Nordfjall K, Stegmayr B, et al. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res, 2008;68(10):3618-3623.
18. Shen J, Gammon MD, Terry MB, et al. Genetic polymorphisms in tel-omere pathway genes, telomere length, and breast cancer survival. Breast Cancer Res Treat. 2012;134(1):393-400.
19. Lu L, Zhang C, Zhu G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res. 2011;13(3):R56.
20. Weischer M, Nordestgaard BG, Cawthon RM, et al. Short telomere length, cancer survival, and cancer risk in 47102 individuals. J Natl Cancer Inst. 2013;105(7):459-468.
21. Epel ES, Merkin SS, Cawthon R, et al. The rate of leukocyte telomere shortening predicts mortality from cardiovascular disease in elderly men. Aging (Albany NY). 2009;1(1):81-88.
22. McTiernan A, Rajan KB, Tworoger SS, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol. 2003;21(10):1961-1966.
23. Irwin ML, Smith AW, McTiernan A, et al. Influence of pre-and postdiag-nosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol. 2008;26(24):3958-3964.
24. Alfano CM, McGregor BA, Kuniyuki A, et al. Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. Psychooncology. 2006;15(11):985-1000.
25. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Social Behav. 1983;24(4):385-396.
26. Patterson RE, Kristal AR, Tinker LF, et al. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol. 1999;9(3):178-187.
27. Breast. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 347-376.
28. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20-37.
29. Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA. 2004;101(49):17312-17315.
30. Parks CG, Miller DB, McCanlies EC, et al. Telomere length, current perceived stress, and urinary stress hormones in women. Cancer Epidemiol Biomarkers Prev. 2009;18(2):551-560.
31. Willeit P, Willeit J, Mayr A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA. 2010;304(1):69-75.
32. Willeit P, Willeit J, Kloss-Brandstatter A, et al. Fifteen-year follow-up of association between telomere length and incident cancer and cancer mortality. JAMA. 2011;306(1):42-44.
33. Heaphy CM, Baumgartner KB, Bisoffi M, et al. Telomere DNA content predicts breast cancer-free survival interval. Clin Cancer Res. 2007;13(23):7037-7043.
34. Adolfsson R, Lenner P, Nordfjall K, et al. The individual blood cell telomere attrition rate is telomere length dependent. PLoS Genet. 2009;5(2):e1000375.
35. Verhulst S, Aviv A, Benetos A, et al. Do leukocyte telomere length dynamics depend on baseline telomere length? An analysis that corrects for "regression to the mean." Eur J Epidemiol. 2013;28(11):859-866.
36. Ornish D, Lin J, Chan JM, et al. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol. 2013;14(11):1112-1120.
37. Giltay EJ, Hageman GJ, Kromhout D. Spurious association between telomere length reduction over time and baseline telomere length. Int J Epidemiol. 2011;40(3):839-840; author reply 840-841.
38. Steenstrup T, Hjelmborg J V, Kark JD, et al. The telomere lengthening conundrum-artifact or biology? Nucleic Acids Res. 2013;41(13):e131.
39. Epel E. How "reversible" is telomeric aging? Cancer Prev Res. 2012;5(10):1163-1168.
40. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res. 1991;196(1):33-39.
41. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol. 2007;8(9):703-713.
42. D'Adda Di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426(6963):194-198.
43. Akbay EA, Pena CG, Ruder D, et al. Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcino-genesis. Oncogene. 2012;32(17):2211-2219.
44. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 1999;97(4):527-538.
45. Genesca A, Pampalona J, Frias C, et al. Role of telomere dysfunction in genetic intratumor diversity. Adv Cancer Res. 2011;112:11-41.
46. Baerlocher GM, Vulto I, de Jong G, et al. Flow cytometry and FISH to measure the average length of telomeres (flow FISH). Nat Protoc. 2006;1(5):2365-2376.
47. Robertson JD, Gale RE, Wynn RF, et al. Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. Br J Haematol. 2000;109(2):272-279.